Dataset Information

Prognostic and predictive value of radiomics signatures in stage I-III colon cancer.

ABSTRACT: Accurate identification of patients with poor prognosis after radical surgery is essential for clinical management of colon cancer. Thus, we aimed to develop death and relapse specific radiomics signatures to individually estimate overall survival (OS) and relapse free survival (RFS) of colon cancer patients. In this study, 701 stage I-III colon cancer patients were identified from Fudan University Shanghai Cancer Center. A total of 647 three-dimensional features were extracted from computed tomography images. LASSO Cox was used to identify the significantly death- and relapse-associated features and to build death and relapse specific radiomics signatures, respectively. A total of 13 death-specific and 26 relapse-specific features were identified from 647 screened radiomics features. The developed signatures can divide patients into two groups with significantly different death (Hazard Ratio (HR): 3.053; 95% CI, 1.78-5.23; P < .001) or relapse risk (HR: 2.794; 95% CI, 1.87-4.16; P < .001). Time-dependent Relative operating characteristic curve showed that the signatures performed better than any other clinicopathological factors in predicting OS (AUC: 0.768; 95% CI, 0.745-0.791) and RFS (AUC: 0.744; 95% CI, 0.687-0.801). Further, survival decision curve analyses confirmed the good clinical utility of the two radiomics signatures. In conclusion, we successfully developed death- and relapse-specific radiomics signatures that can accurately predict OS and RFS, which may facilitate personalized treatment.

SUBMITTER: Dai W

PROVIDER: S-EPMC7240849 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Prognostic and predictive value of radiomics signatures in stage I-III colon cancer.

Dai Weixing W Mo Shaobo S Han Lingyu L Xiang Wenqiang W Li Menglei M Wang Renjie R Tong Tong T Cai Guoxiang G

Clinical and translational medicine 20200101 1

Accurate identification of patients with poor prognosis after radical surgery is essential for clinical management of colon cancer. Thus, we aimed to develop death and relapse specific radiomics signatures to individually estimate overall survival (OS) and relapse free survival (RFS) of colon cancer patients. In this study, 701 stage I-III colon cancer patients were identified from Fudan University Shanghai Cancer Center. A total of 647 three-dimensional features were extracted from computed tom ...[more]

PMID: 32508036

Similar Datasets

Project description:The prognostic value of BRAF and KRAS mutations within microsatellite-unstable (MSI) and microsatellite-stable (MSS) subgroups of resected colon carcinoma patients remains controversial. We examined this question in prospectively collected biospecimens from stage III colon cancer with separate analysis of MSI and MSS tumors from patients receiving adjuvant FOLFOX +/- cetuximab in two adjuvant therapy trials.Three groups were defined: BRAF Mutant, KRAS Mutant, and double wild-type. The analytic strategy involved estimation of study-specific effects, assessment of homogeneity of results, and then analysis of pooled data as no differences in patient outcome were found between treatment arms in both trials. Associations of mutations with patient outcome were analyzed, and multivariable models were adjusted for treatment and relevant factors.Four thousand four hundred eleven tumors were evaluable for BRAF and KRAS mutations and mismatch repair status; 3934 were MSS and 477 were MSI. In MSS patients, all BRAF V600E mutations (hazard ratio [HR] = 1.54, 95% confidence interval [CI] = 1.23 to 1.92, P < .001), KRAS codon 12 alterations, and p.G13D mutations (HR?=?1.60, 95% CI?=?1.40 to 1.83, P < .001) were associated with shorter time to recurrence (TTR) and shorter survival after relapse (SAR; HR?=?3.02 , 95% CI?=?2.32 to 3.93, P < .001, and HR?=?1.20, 95% CI?=?1.01 to 1.44, P = .04, respectively). Overall survival (OS) in MSS patients was poorer for BRAF-mutant patients (HR?=?2.01, 95% CI?=?1.56 to 2.57, P < .001) and KRAS-mutant patients (HR?=?1.62, 95% CI?=?1.38 to 1.91, P < .001) vs wild-type. No prognostic role of KRAS or BRAF mutations was seen in MSI patients. Furthermore, no interaction was found between treatment arm (with or without cetuximab) and KRAS and BRAF mutations for TTR or OS in MSS patients.In a pooled analysis of resected stage III colon cancer patients receiving adjuvant FOLFOX, BRAF or KRAS mutations are independently associated with shorter TTR, SAR, and OS in patients with MSS, but not MSI, tumors. Future clinical trials in the adjuvant setting should consider these mutations as important stratification factors.

Dataset Information

Prognostic and predictive value of radiomics signatures in stage I-III colon cancer.

Publications

Prognostic and predictive value of radiomics signatures in stage I-III colon cancer.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets